Last quarter (Q4 2023), X4 Pharmaceuticals's total revenue was $49.00K, a decrease of -50.00% from the same quarter last year. In Q4, X4 Pharmaceuticals's net income was $-19.13M. See X4 Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 195.00K	$ 195.00K	-	$ 196.00K	$ 3.00M	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 195.00K	$ 195.00K	-	$ 196.00K	-	-
Operating Expense	$ 107.52M	$ 107.52M	$ 87.57M	$ 75.35M	$ 62.87M	$ 47.80M
Operating Income	$ -107.52M	$ -107.52M	$ -87.57M	$ -75.35M	$ -59.87M	$ -47.80M
Net Non Operating Interest Income Expense	$ 4.24M	$ -1.20M	$ -3.77M	$ -3.63M	$ -2.42M	$ -950.00K
Other Income Expense	$ -2.19M	$ -7.63M	$ 1.99M	$ -60.00K	$ 306.00K	$ -4.05M
Pretax Income	$ -101.09M	$ -101.09M	$ -93.84M	$ -88.68M	$ -61.98M	$ -52.81M
Tax Provision	$ 78.00K	$ 78.00K	$ 28.00K	$ 17.00K	$ 148.00K	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -101.17M	$ -101.17M	$ -96.41M	$ -102.64M	$ -62.13M	$ -53.40M
Basic EPS	-	-	-	-	$ -3.09	$ -4.63
Diluted EPS	-	-	-	-	$ -3.09	$ -4.63
Basic Average Shares	-	-	-	-	$ 20.08M	$ 11.53M
Diluted Average Shares	-	-	-	-	$ 20.08M	$ 11.53M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	$ 0.20	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 107.52M	$ 107.52M	$ 87.57M	$ 75.35M	$ 62.87M	$ 47.80M
Net Income From Continuing And Discontinued Operation	$ -101.17M	$ -101.17M	$ -93.87M	$ -88.70M	$ -62.13M	$ -52.81M
Normalized Income	$ -60.39M	$ -79.86M	$ -74.13M	-	$ -61.69M	$ -48.24M
Interest Expense	-	-	-	-	$ 2.69M	$ 2.15M
EBIT	$ -101.59M	$ -95.31M	$ -89.85M	$ -85.05M	$ -59.30M	$ -50.66M
EBITDA	$ -17.15M	$ -94.89M	$ -89.33M	$ -84.55M	$ -58.94M	$ -50.56M

Currency in USD

X4 Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing